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Translocation mechanismP-glycoprotein (P-gp) iswell known formultidrug resistance in drug therapy. Its over-expression results into the
increased efﬂux of therapeutic agents rendering them inefﬁcacious. A clear understanding of P-gp efﬂuxmecha-
nismand substrate/inhibitor interactions during the course of efﬂux cyclewill be crucial for designing effective P-gp
inhibitors, and therapeutic agents that are non-substrate to P-gp. In the present work, we have modeled P-gp in
three different catalytic states. These models were utilized for elucidation of P-gp translocation mechanism using
multi-targeted molecular dynamics (MTMD). The gradual changes occurring in P-gp structure from inward open
to outward open conformation were sampled out. A detailed investigation of conformational changes occurring in
trans-membrane domains (TMDs) during the course of catalytic cycle was carried out. Movements of each TM he-
lices in response to pronounced twisting and translatorymotion of NBDs were measured quantitatively. The role of
intracellular coupling helices (ICHs) during the structural transition of P-gp was studied, and observed as vital links
for structural transition. A close observation of displacements and conformational changes in the residues lining
drug-binding pocket was also carried out. Further, we have analyzed the molecular interactions of P-gp sub-
strates/inhibitors during the P-gp translocation to ﬁnd out how stable binding interactions of a compound at
drug-binding site(s) in open conformation, becomes highly destabilized in closed conformation. The study revealed
striking differences between the molecular interactions of substrate and inhibitor; inhibitors showed a tendency to
maintain stable binding interactions during the catalytic transition cycle.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
In 1976, Ling and Juliano introduced a permeability glycoprotein
(P-glycoprotein, P-gp) that efﬁciently “pump” substrates out of tumor
cells through an ATP-dependent mechanism in an unidirectional
fashion [1]. P-gp is a member of ATP-binding cassette (ATP) transporter
proteins, also known as ABCB1 or MDR1. It is expressed at cellular level
and function as xenobiotic monitor protecting cells from toxicants [2].
Over-expression of P-gp is associatedwith increased efﬂux of therapeutic
agents from their site of action. Thus, its over-expression has resulted in
the reduced efﬁcacy of many therapeutic agents like anticancer agents,
antiviral agents, calcium channel blockers, neuroleptics, antiarrythmics,
antimalarials and antifungals [3]. Moreover, substrate promiscuity
confers this protein an abnormal ability to efﬂuxout chemically unrelatedformatics, National Institute
agar, Punjab 160 062, India.
.drugs. P-gp efﬂuxes out substrates ranging from approximately 300 to
4000 Da in mass, for instance mitomycin (334 Da), amisulpride
(362 Da), ﬂupheanzine (437 Da), daunorubicin (527 Da), docetaxel
(807 Da), rapamycine (914 Da), and cyclosporine (1202 Da) [4–6].
P-gp has 1280 amino acid residues, constituting a molecular mass
of approximately 170 kDa. Structurally, P-gp is a single polypeptide
comprising of two homologous halves; each consisting of a trans-
membrane domain (TMD) and a nucleotide binding domain (NBD).
The two homologous parts are separated by an intracellular linker
region of about 60 amino acid residues. Each TMD consists of six
membrane spanning helices arranged in a speciﬁc pattern. Both TMDs
are arranged together to form a large highly hydrophobic cavity that
could accommodatemultiple substrates. TheNBDs are highly conserved
regions, and are sites of ATP binding/hydrolysis [7–9].
P-gp has been crystallized in different catalytic forms from different
organisms, but the crystal structure of human P-gp is not yet available.
Recently, human mitochondrial P-gp crystal structure has been
published in complex with nucleotide analogs [PDB IDs: 4AYT (rod
form A), 4AYX (rod form B), 4AYW (plate form)], and in a ligand-free
apo form [PDB ID: 3ZDQ] [10]. The bacterial P-gp crystal structures
with relatively good resolution reported prior to 2007 were Sav1866
(Staphylococcus aureus transporter) and MsbA [11,12]. These bacterial
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human P-gp. MsbA crystallographic structure was used to model
human P-gp in open conformation (drug-binding cavity open to intra-
cellular space, NBDs far apart). Sav1866 crystallographic structure was
utilized to model closed conformation (drug-binding cavity open to
extracellular space, NBDs in close proximity). The three murine P-gp
crystallographic structures [13] (PDB IDs: 3G5U, 3G60 and 3G61) pub-
lished by Aller et al. in 2009, were promising templates for modeling
human P-gp in open conformation. However, in a recently published
Caenorhabditis elegans P-gp crystal structure [14], Jin et al. have pointed
out signiﬁcant register errors in TM3, TM4 and TM5 regions in the
murine P-gp crystallographic structure (corrected structure has been
recently published [15]). Corrections in these errors are relevant to the
identiﬁcation of drug-interacting amino acids and an accurate deﬁnition
of the NBD–TMD interface. Thus, the model built from murine P-gp is
not much reliable for substrate binding studies. However, the crystallo-
graphic structure of C. elegansP-gp,with a resolution of 3.4 Å, shares less
sequence identity (49%) to human P-gp as compared to that of murine
P-gp (87%), but the similarities between their amino acid sequences
and functional properties suggest that the structure of C. elegans P-gp
is a reasonable starting point for substrate binding studies and mecha-
nistic understanding of human P-gp [14].
Molecular dynamics studies have been predominantly used for
elucidation of translocation mechanism and substrate binding of P-gp.
Detailed depictions of ATP hydrolysis mechanisms and conformational
changes taking place in response to hydrolysis were reported from
MD studies on isolated NBDs [16–26]. Furthermore, full-length ABC
transporter molecular dynamics simulations [27–36] gave insights
into the conformational changes in TMDs and substrate binding site
during substrate translocation. Recently, using MD studies researchers
have reported the effect of surrounding environment on the structure
and function of P-gp [37] and importance of linker region in the stability
of P-gp structure [38]. However, inmost of these studiesmurine crystal-
lographic structure was used as template for human P-gp model
building, which raises some dubiety of these studies regarding register
error in murine P-gp structure.
In the present study, we have employedmulti-targetedmolecular
dynamics (MTMD) technique to trace out catalytic transition cycle of
P-gp efﬂux pump. The technique employs addition of an extra term
to the energy function based on the mass-weighted root mean
square deviation of a set of atoms in the current structure compared
to the reference structure. Using MTMD, multiple reference struc-
tures can be speciﬁed through which the speciﬁed structure will
move. The present structure is ﬁtted to the target structure by the
application of a force vector calculated to decrease the RMSD be-
tween the two structures.
Human P-gp was modeled in three different catalytic states; inward
open (IO) (NBDs far apart), intermediate open (IIO) and outward open
(OO) (NBDs in close proximity). Inward open catalytic structure of
human P-gp was taken from our previously reported model developed
using C. elegans P-gp crystal structure as a template [39]. The other
two catalytic states; intermediate inward open and outward open
weremodeled using humanmitochondrial P-gp and Sav1866 P-gp crys-
tal structures as templates, respectively. The three catalytic structures
were subjected to MTMD simulation to gain valuable insights into the
P-gp efﬂux mechanism. In-depth analysis of shifts in TMDs was carried
out during the course of catalytic cycle. Quantitative measurement of
movement of NBDs and ICHs was performed. The stretching of TMs in
correspondence with movement of intracellular coupling helices
(ICHs) was also noticed. A detailed analysis of conformational changes
occurring at drug-binding site and, the relative changes in distance
and angles of drug-binding residueswas carried out. A relation between
the conserved apical interactions and the twisting movement of NBDs
was noticed. Hydrophobic substrate gates were also observed during
MTMD simulations. Furthermore, MTMD simulations were carried out
with known substrates and inhibitors of P-gp to ﬁnd out the relativedifference in their binding pattern and the motion path they follows
when efﬂux out by P-gp. A clear difference was noticed between
substrates and inhibitors interactions during the course of P-gp structural
transition. Most of the results well correlatedwith large body of reported




Human P-gp homology model in IO catalytic state was utilized from
our previous study. C. elegans P-gp crystallographic structure was taken
as a template to model IO catalytic state. Human mitochondrial P-gp
(PDB ID: 4AYT) and Sav1866 P-gp crystal structures were used
to model IIO catalytic state and OO catalytic state of human P-gp,
respectively. The amino acid sequences of human P-gp, humanmito-
chondrial P-gp and Sav1866 P-gp were retrieved from UniProtKB/
TrEMBL database, primary accession numbers P08183, Q9NRK6 and
Q99T13, respectively. Sequence alignment was performed on ClustalW
(Figs. S1 and S2), using a gap penalty of 10 and a gap extension penalty
of 0.05. Subsequently, homology modeling of human P-gp was
performed on MODELLER 9v8. The linker region was not modeled.
The initially generated models were evaluated by Ramachandran
plot and Errat plot using PROCHECK program in SAVES server. The
iterative loop reﬁnement and energy minimization were performed
to reﬁne the obtained homology model.
2.2. Induced ﬁt docking
2.2.1. Preparation of model and ligands for the IFD protocol
The 3D structures of the P-gp substrates and inhibitors were built on
Sybyl7.1 software package. All 3D structures wereminimized by Powell
method. The minimization was terminated when the energy gradient
convergence criteria of 0.05 kcal/mol ∗ Å was reached or 2000 steps of
minimization cycle were exceeded. Table S1 shows the list of substrates
and inhibitors used in docking experiments.
Protein preparationwizard of Schrödinger suite 9.0.211was used for
structural preparations of P-gp homology model. The protein prepara-
tion includes the addition of hydrogen atoms, optimization of hydrogen
bonding networks, and minimization of protein to RMSD 0.30 Å, using
Optimized Potential for Liquid Simulations (OPLS) 2005 force ﬁeld.
The selected ligands were prepared in LigPrep and minimized using
OPLS 2005 force ﬁeld.
2.2.2. Induced-ﬁt docking protocol
The IFD protocol asmentioned in IFDmanual of Schrödinger 9.0.211,
was followed. [40,41] In brief, Schrödinger suite uses two modules,
Glide and Prime to perform IFD. The ligand ﬂexibility and the receptor
ﬂexibility are accounted by Glide and Prime, respectively. IFD was per-
formed in following steps. (i) The receptor was minimized applying
constrain (Glide protein preparation, reﬁnement only) with an RMSD
cutoff of 0.18 Å. (ii) A softened potential (van der Waals radii scaling)
was used for initial Glide docking of each ligand. Twenty poses per
ligand that had a Coulomb–vdW score less than 100 and an H-bond
score less than 0.05 were retained. (iii) Each protein–ligand complex
was subjected to one round of Prime side chain prediction. In our
study, residues of active site(s) were deﬁned instead of considering
residues within the cutoff distance from the ligand. (iv) The same set
of residues and the ligand for each protein–ligand complex poses
were minimized by Prime. Each pose of receptor structure reﬂected an
induced ﬁt to the ligand structure and conformation. (v) The protein–
ligand complexes within a speciﬁed energy of the lowest-energy
structure (default 30 kcal/mol) were subjected to Glide re-docking.
The ligand was then rigorously docked, using default Glide settings,
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energy (IFD Score) for each output pose.
Residues reported in experimental studies [42–45] that have been
implicated in drug bindingwere speciﬁed for active site grid generation
(listed in supplementary information, Table S2). The ligand docking
calculationswere done on the standard precisionmode of Glide software.
2.3. Molecular dynamics simulations
The generated homologymodelswere embedded into POPC lipid bi-
layer. CHARMM-GUI Lipid Builderwas used to embed protein structures
into lipid bilayer. The coordinates of lipid bilayer were taken from OPM
database. The lipid–protein systems were solvated using TIP3P water
model and neutralized by the addition of counter ions. The CHARMM-
GUI generated PDB ﬁles were reformatted to ﬁles that conform to the
Lipid11 force ﬁeld naming convention using charmmlipid2amber.x
script. AMBER99SB force ﬁeld was used for the parameterization of
protein and Lipid 11 force ﬁeld was used for the parameterization of
POPC lipid. The ﬁnal system of each membrane embedded homology
model contained 340 lipid molecules, 44,313 solvent molecules, Mg2+
ion, ATP, ADP, Pi, 14 Na+ and 26 Cl− ions, constituting 1,96,939 total
number of atoms (Figs. S3).
Minimization of the protein–lipid systems was carried out in two
successive steps. Firstly, the proteinwas restrainedwith a force constant
of 50 kcal/mol/Å2, and only solvent and lipid phase were minimized
with 500 cycles of each steepest descent and conjugate gradient
methods. In the second step, whole system was minimized with
500 cycles of both steepest descent and conjugate gradient. The systems
were gradually heated to 310 K on NVT ensemble for 50 ps, where the
protein was restrained with a force constant of 20 kcal/mol/Å2.
Equilibration was performed on NPT ensemble at 310 K temperature
and 1 atm pressure for 50 ns with a restraint force constant of
20 kcal/mol/Å2 on the protein. For entire simulation the step size
was kept 2 fs. During the MD run all bonds containing hydrogen
atoms were constrained using SHAKE algorithm. Langevin thermostat
and barostat were used for temperature and pressure coupling. The
non-bonded cutoffwas kept at 8 Å, and long-range electrostatic interac-
tions were treated by the Particle–Mesh Ewald (PME) method.
2.4. Multi-targeted molecular dynamics simulations
All MTMD simulations were carried out on AMBER 12. The equili-
brated protein–lipid systems were subjected to MTMD simulations.
The IO catalytic transition state was taken as initial structure and, IIO
and OO catalytic states of P-gp were taken as reference structures. The
root mean square deviation between IO and IIO was 8.69 Å and that
between IO and OO was 12.46 Å. The IO was ﬁrst targeted to IIO and
then to OO transition state to trace out the catalytic cycle. The present
structure was ﬁtted to the target structure by the application of a force
vector calculated to decrease the RMSD between two structures. An
additional term to the energy function based on the mass-weighted
root mean square deviation of a set of atoms in the current structure
compared to a reference structure is added by the MTMD simulation
package of AMBER 12.
Prior to MTMD simulations of protein–ligand systems, the ligand
from best docked pose of each protein was extracted. The atomic
charges for ligands were derived with AM1-BBC method implemented
in Antechamber program of AmberTools. General amber force ﬁeld
(GAFF) was used to generate missing parameters of ligands using
Parmchk module of Antechamber. The protein–ligand system was
then embedded into POPC lipid bilayer and subjected to molecular
dynamics simulation, following the similar protocol mentioned above
to get an equilibrated structure for MTMD simulation. The simulation
studies consisted of total 17 systems (16 with ligand and one initial
without ligand). Each system was subjected to 50 ns of equilibrationand 50 ns of MTMD simulation. Ptraj module of Amber tools, VMD,
Pymol and xmgrace were used for trajectory analysis.
3. Results and discussion
3.1. Models of catalytic transition structures
P-gp efﬂux pump undergoes a large body of structural transforma-
tion from fully open inward (NBDs are far apart) to fully open outward
(NBDs in close proximity) conformation state. The crystal structure
of P-gp is available in different catalytic forms. In this study, we have
modeled human P-gp in three different catalytic states utilizing crystal-
lographic structural templates of C. elegans P-gp, human mitochondrial
P-gp and Sav1866 P-gp. Though, both C. elegans P-gp and human
mitochondrial P-gp crystal structures (PDB ID: 4AYT) are in inward
open conformation, the distances between their NBDs with respect to
C-α atom of conserved glutamate residues (E556 and E1201) are 39.5
Å and 26.5 Å, respectively. The respective distance in Sav1866 P-gp is
14.3 Å. Thus, mitochondrial P-gp could be utilized as an intermediate
structure between inward open and outward open state for studying
the catalytic transformation of P-gp. Moreover, the model generated
from C. elegans P-gp was used as starting structure because it showed
maximum consistency with reported biochemical and biophysical
data [42–59] (discussed in detail further in text).
Themodel of human P-gp in inward open state built using C. elegans
P-gp as template was taken from our previously reported model [39].
The models of human P-gp in intermediate inward open state and
outward open state were generated using mitochondrial P-gp and
Sav1866 P-gp as templates, respectively. The sequence identity of
human P-gp with mitochondrial P-gp is 41% and that with Sav1866 is
17%. Sequence alignment was performed on ClustalW (Figs. S1 and
S2). ClustalW alignments were used to generate homology models
using MODELLER 9v8 software following similar procedure as reported
in our previous study [39]. 100 structures were generated and ten best
modeled structures were selected on the basis of dope score, and
RMSD with respect to crystal structure. The quality of these models
was further analyzed with Errat plot and their dihedral angle
distributions were analyzed using Ramachandran plot (Figs. S4 and
S5). Ramachandran plot of human P-gp homology model generated
using mitochondrial P-gp as a template (Fig. S4) showed two residues
in the disallowed region. The overall quality factor of homology model
was 94.91% in Errat plot. Ramachandran plot of human P-gp homology
model generated using Sav1866 as a template (Fig. S5) showed four
residues in the disallowed region. The overall quality factor of homology
model was 89.91% in Errat plot.
3.2. MTMD
MTMD simulations were performed to incur a better understanding
of P-gp translocation mechanism. The technique could be utilized to
transform inward open structure of P-gp to outward open through
speciﬁed intermediate structures. MTMD is a unique technique in
which important intermediate catalytic structures could be sampled
out, as the P-gp structure transforms from IO to OO state. A quantitative
analysis of conformational changes occurring at drug-binding site could
be performed and a better understanding of conformational changes
responsible for the loss of stable binding interaction of substrate in OO
state could be obtained.
The human P-gp homology model generated from C. elegans P-gp
template was taken as starting structure for MTMD simulation. The IIO
state and OO state models generated using human mitochondrial P-gp
and Sav1866 P-gp templates, respectively, were taken as targeted
structures. The coordinates of IO state model were forced to IIO state
and then to OO state using residue mask and applying force constant
proportional to difference between RMSD of reference and target
structure. During simulation it was observed that the NBDs gradually
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catalytic dyad. When viewed from intracellular side, stretching of
TM helices can be noticed in correspondence to NBD movements. It
appeared as the NBDs were pushing TM helices in a speciﬁc pattern,
ﬁnally exposing the drug-binding region to extracellular space. From
extracellular view, it can be clearly observed how pliers like the
action of NBD result in opening of TMDs in a speciﬁc pattern; not
the two TMDs move apart, rather parts of each move apart. The
TM1 and 2, of TMD1 and TM9, 10, 11, and 12 of TMD2 move apart
from TM3, 4, 5, and 6, of TMD1 and TM7 and 8, of TMD2 (see supple-
mentary information, Movie 1). The MTMD trajectory was quantita-
tively analyzed for shifts in TMDs, ICH movement in conjunction
with NBDs, and stretching in TM helices corresponding to ICH and
NBDmovements. The placement of ATP-Mg2+-H2O at NBDs support-
ed alternating site mechanism of ATP hydrolysis [60]. As per recent
study of Oldham and Chen [61] that strongly supported the general
base ATP hydrolysis mechanisms, ATP-Mg2+-H2O complex was
ﬁrst placed in NBD1 and ADP and Pi at NBD2. The structure was
stable and complex formed stable binding interactions with E556.
Subsequent MD trials were also conducted placing ATP-Mg2+-H2O
complex at both NBDs and, ATP-Mg2+-H2O complex at NBD2 and
ADP at NBD1, but none gave stable conformation. Similar observa-
tions were also reported in another simulation study conducted by
Wise [62]. All further simulations were carried out placing ATP-
Mg2+-H2O at NBD1 and, ADP and Pi at NBD2. Moreover, the confor-
mational changes occurring at drug-binding site during the course of
simulation, and the corresponding distance and angular changes in
drug-binding residues were also analyzed. Interestingly, we noticed
a correlation between conserved apical interactions and NBD move-
ment. The hydrophobic substrate gates were also observed during
the course of MTMD simulation. Furthermore, MTMD simulations
of substrates and inhibitors gave important insights into their molec-
ular interaction differences during the structural transition of P-gp.3.2.1. Movement of NBDs and intracellular coupling helices (ICHs)
Before discussing the movements of NBDs during MTMD simula-
tions, it is worthwhile to mention the communication links between
NBDs and TMDs. There is a single physical linkage between each NBD
and TMD, viz. a loop region (D398-K418) connecting TM6 of TMD1
with NBD1 and another loop region (K1064-G1083) connecting TM12
of TMD2 with NBD2. The other possible communications are non-
bonded interactions between NBD and ICH. Out of four ICHs, the ICH1
and ICH4 form a ball and socket like joint with NBD1 and, ICH2 and
ICH3 form ball and socket like joint with NBD2 (Fig. 1). These ICH forms
conserved salt bridge and H-bonding interactions with correspondingFig. 1. Arrangement of ICHs on NBDs, ICH2 and ICH4 are arranged in the grove formed by
lobe 1 [ATP binding core subdomain (blue)+beta-subdomain (wheat)] and lobe 2 [helical
subdomain (red)]. The color coding of other conserved region are: A-loop—green,
Walker-A—cyan, P-loop—orange, Signature/C-motif—yellow, Walker-B—violet.residues in NBDs. ICH1 is a short helix between TM2 and TM3 that insert
into the groove of NBD1 near Walker-A region and form close contact
with A-loop. ICH3, a short helix between TM8 and TM 9, position itself
into the groove of NBD2. ICH2 and ICH4 are short helices between TM4
and TM5, and TM10 and TM11, respectively. These helices are inserted
into the groove of opposite half NBD formed by the three subdomains;
ATP binding core subdomain (blue), beta-subdomain (wheat) and helical
motif (red) (Fig. 1). A detailed list of ICH residues interacting with
different parts of NBD and TM helices is provided in Table S3.
As the simulation progressed the separation between NBD1 and
NBD2, measured with respect to conserved glutamate residues (Glu
556 and Glu 1201) reduces from 39 Å in IO state to ~14 Å in OO state.
Interestingly, it was observed that the NBDs do not follow a straight
line path as they approach each other rather they rotate with respect
to each other. Fig. 2 represents themovement of NBD during the course
of MTMD simulation. In the initial stage of IO to IIO transition the NBDs
showed a twisting movement.
The ICHs showed a concerted movement with NBDs. As ICH moved
along with NBD it was noticed that most of the conserved interactions
between NBD and ICH maintained during IO to IIO state transition of
P-gp structure. The conserved salt bridge interactions between Arg
905 (ICH4), Asp 164 (ICH1) and Tyr 444 (NBD1), and that in between
Arg 262 (ICH2), Asp 805 (ICH3) and Tyr 1087 (NBD2), disrupted
gradually as the simulation progressed from IIO to OO catalytic
state (Fig. 3). This was due to the rotation of ICH1 and ICH4 by
~20○and ~82○, respectively, about their horizontal axis (Fig. 4A and B).
ICH3 and ICH2 also showed a rotation of ~30○ and ~46○, respectively,
about their horizontal axis (Fig. 4). During the course of simulation the
ICH2 and ICH4 also showed a pivot of ~30○ about their vertical axis.
Fig. 3 depicts the ball and socket-like movement of ICHs during the
course of simulation. Initially, in IO state the ICHs were well ﬁtted into
the corresponding grooves of NBDs and as the simulation progressed
they rotated into the groove occupying their original position. This
combined rotator and translator movements of ICHs prompted us to
investigate the relative effects of their movements on the connected
TM helices.
3.2.2. Rearrangements in TMDs
The rearrangements in TMDs resulted not only due to translatory
motion of NBDs, but also due to rotatory motion of NBDs. In depth anal-
ysis revealed that the separation of TMDs occurs in a speciﬁc pattern,
which resulted due to the arrangement pattern of TMs (Fig. 5),
i.e., (i) TM4 and 5 of TMD1 interact with NBD2 and TM10 and TM11
of TMD2 interact with NBD1, (ii) TM6 and TM12, which form physical
linkage with NBDs, connects to their respective NBD intersecting the
inverted “V” formed by TM3 and TM4 (in case of TM6), and TM9 and
TM10 (in case of TM12). Thus, as the NBD moves close, accompaniedFig. 2.Distance between two NBDsmeasure with respect to distance between Cα-atom of
conserved residues E556 and E1201.
Fig. 3. The conserved salt bridge interactions between Arg 905 (ICH4), Asp 164 (ICH1) and Tyr 444 (NBD1), and that in between Arg 262 (ICH2), Asp 805 (ICH3) and Tyr 1087 (NBD2).
These interactions remained intact till IIO conformational state (4 ns), then disrupted gradually as the simulation progressed from IIO to OO catalytic state.
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opening of the TMDs in a plane perpendicular to themovement of NBD.
A quantitative investigation of movements in TMs helices was per-
formed. The distance between adjacent TMs, and TMs facing each
other in the two TMDs were plotted during the course of simulation.
Figs. 6, 7 and 8 (also see supplementary Fig. S6 for the top view from
extracelluar side) depict the separation between different TMs during
the IO to OO conformational change of P-gp. Three types of distance
plot were plotted: (i) distance between top residues (residue toward
extracellular region) of the TM helices (ii) distance between bottom
residues (residue toward NBD on helix) of TM helices and (iii) distance
between center of mass (COM) of the TM helices. The distance of TM1
was measured with respect to TM2 and TM7, as TM2 is adjacent to
TM1 and TM7 was in front of TM1. The initial distance between W55
(bottom residue, TM1) and V711 (bottom residue, TM7) was ~64 Å in
IO state, which changed to ~51 Å in OO state (Fig. 6A). Similarly, the dis-
tance between E86 (top residue, TM1) and V736 (top residue, TM7)
changed from ~16 to 35 Å. In contrast, when the COMdistance betweenTM1 and TM7 was plotted, no noticeable change was observed, this
indicated that the TMs moved around a ﬁxed point analogous to a
lever/pry-like action. The distance between TM1 and TM2 decreased,
and the top residues (E86, TM1 and L107, TM2) moved from ~14 Å to
7 Å, while the bottom residues (Y55, TM1 and R157, TM2) moved
from ~32 Å to 27 Å (Fig. 6B). Similar trend was noticed for TM1–TM2
COM movement (moved closed by ~4 Å), indicating that TM1 moved
along with TM2 in same direction. A large body of conformational rear-
rangement was noticed in case of TM2 and TM3, the helices that were
also connected to ICH1. The top residues (L107, TM2 and R210, TM3)
moved apart from ~23 Å to 33 Å, while the bottom residues (R157,
TM2 and V158, TM3) came close from ~23 Å to ~17 Å (Fig. 6C). An
approximate separation of 4 Å was observed between COM of both
helices. This particular rearrangement was only possible if there was a
twisting motion along with translatory motion between two helices;
implicating the angular rotation of ICH1 and twisting ofNBDs. Themove-
ment between TM7 and TM8 was similar to that of TM1 and TM2. Both,
TM7 and TM8 showed concerted movement in same direction, the
Fig. 4.Changes in angles between Cα-atoms of ICH residues andNBD residues. (A) angular
rotation between Cα-atoms of ICH2, ICH3 and NBD2 residues Arg 262-Thr 263-Val264
(black), Asp 805-Asp 806-Pro 807 (green) and Tyr 1087-Asp 1088-Pro 1089 (red),
respectively. (B) angular rotation between Cα-atoms of ICH4, ICH1 and NBD1 residues Arg
905-Thr 906-Val 907 (black), Asp 164-Val 165-His 166 (red) and Tyr 444-Asp 445-Pro 446
(green), respectively.
Fig. 5. Arrangement pattern of TMs (number shown in rectangular box) and type of
linkage between TMs and NBDs. Solid blue line indicate physical linkage via loop region
and dotted red line indicate linkage through non-bonded interactions. The image in
cartoon representation shows how inverted V like structure formed by TM3 and TM4,
and TM9 and TM10 is intersected by TM6 and TM12, respectively.
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residues (V711, TM7 and Q797, TM8) and COM changed by ~2 Å
(Fig. 7A). Similar to TM2 and TM3 connected to ICH1, TM8 and TM9
were connected to ICH3, which form non-bonded contacts with
NBD2. The distance between COM and bottom residues (Q797, TM8
and L812, TM9) changed by ~3 Å, whereas the distance between
top residues (T745, TM8 and W853, TM9) increased by ~15 Å
(Fig. 7B). This implicated the angular rotation of ICH3 and twisting
of NBDs, similar to that noticed in case of TM2 and TM3.
As per the reported experimental data, TM2, TM3, and TM8 do not
participate in ligand binding and their conformational changes ob-
served during IO to OO transition of P-gp structuremay not affect ligand
binding, but their movement and conformational changes had a major
contribution in TMD rearrangement cascade. The residues on TM4,
TM5, and TM6 of TMD1, and TM9, TM10, TM11 and TM12 of TMD2
that face toward the hydrophobic cavity of P-gp structure in IO state
have been reported to participate in ligand binding (list of these resi-
dues is provided in supplementary information, Table S2). Further, the
movements of these TMs were analyzed. During the IO to OO catalytic
state transition of P-gp structure, prominent changes in distance and
conformations were observed between T4 and TM10, TM5 and TM11,
and TM6 and TM9. Initially, the bottom residues (A259, TM4 and
V905, TM10) of TM4 and TM10 had a separation of ~44 Å in IO state,
which decreased to 22 Å in OO state (Fig. 7C). Similarly, the bottom
residues of TM5 and TM11 came close by ~22 Å (Fig. 8A). Moreover,
TM4 and TM5 and TM10 and TM11 are connected to ICH2 and ICH4,respectively; theirmovements could be directly correlated to themove-
ments of both the ICHs. TM6, which is directly connected to NBD1, and
TM9 connected to ICH3 also showed a decrease from 45 Å to 25 Å
between their bottom residues (I368, TM6 and L812, TM9) (Fig. 8B).
TM6 and TM12 are TM helices physically connected to NBD1 and
NBD2, respectively, and their movements directly correspond to the
movements in NBDs. The initial separation between bottom residues
(I368, TM6 and K1012, TM12) of these TMs was ~52 Å in IO state,
which gradually decreased to ~38 Å in OO state (Fig. 8C). A similar
study performed byWise [62] using muring, Sav1866 and MsbA as tar-
get structures provides valuable insights into P-gp efﬂux mechanism
and TMD rearrangement. We further tested our simulation protocol
by simulating similar targets. The results obtained were similar to
those reported by Wise. This further validated our simulation protocol.
Fig. S7 provide a comparison of both MTMD simulations. However,
both the simulations provide similar insights in TMD rearrangement,
but the murine crystallographic structure has been reported to have
certain register errors which may raise concerns regarding the drug-
binding residues lining TM4 and TM5 (discussed further in text).
On collective observation of distance plots between the TM helices
involved in ligand/drug binding, it was inferred that in most of the
cases the change in distance between the top residues and COM was
less pronounced as compared to the bottom residues. Thus, there
were nomajor displacements in the upper half of these helices as com-
pared to lower one. Therefore, it indicates that along with displace-
ments, the conformational changes in the residues in these TMs
majorly contribute to the loss of ligand/drug binding at drug-binding
site in OO state.
Further, to analyze the displacement of individual TMhelix, RMSD of
each TM was plotted. Fig. 9 depicts the RMSD plots of TM helices. The
RMSD plots revealed that TM1, TM3 and TM4 of TMD1 (Fig. 9A), and
TM9, TM10 and TM12 of TMD2 showed higher RMSD (Fig. 9B).
3.2.3. Conformational changes at DBS and correlationwith biochemical and
biophysical data
Many efforts have beenmade to date to characterize the DBS of P-gp.
A signiﬁcant amount of studies have been performed by Loo and
Clarke [42–45,49,52,54,55,63], and some other important were those
published by Dey et al. [64], Pascaud et al. [65], Shapiro et al. [66] and
Lugo et al. [67] Loo and Clarke used cysteine or arginine scanningmuta-
genesis [49,52] to identify drug-binding residues. In these studies they
identiﬁed seven residues protected by verapamil. A novel approach of
arginine scanning mutagenesis was used by Loo and Clarke to locate
residues in P-gp structure that faced toward DBS. These studies were
Fig. 6. Relative displacements in TM helices from IO to OO structural transition, initial IO conformation is represented as transparent blue ribbon. The adjacent distance versus time plot
shows the quantitative data of the corresponding TMhelices duringMTMD simulation. A, B and C represent displacements in TM1 and TM7, TM1and TM2, and TM2 and TM3, respectively.
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side chain, when present in the drug-binding site, mimicked the rescue
of folding of certain mutations by transport substrates. Another, 16
residues were identiﬁed using dibromobimane studies [44,45,52].
Thio-reactive rhodamine B analog and MTS-verapamil studies were
used to identify residues on TM5 and TM6 [55]. On the basis of studies
conducted by Dey et al., Pascaud et al., Shapiro et al. and Lugo et al. it
may be proposed that P-gp has four binding sites. All drug-binding
residues, those identiﬁed by Loo and Clarke, Aller et al. [13], Jin et al.
[14] and the authors mentioned above were analyzed for their location
and respective conformational changes in drug-binding site.
The reported studies depicted that the drug-binding residues
were distributed on TM1, TM4, TM5, TM6, TM7, TM9, TM10, TM11
and TM12 in the hydrophobic cavity of P-gp. The generated model
was consistent with these biochemical data. The MTMD trajectories
were analyzed with the aim to ﬁnd out the conformational changes
and displacements occurring in these drug-binding residues thatrendered loss of stable substrate binding interactions. The movements
of these residues during the course of simulation are shown in supple-
mentary information Movie 2. Fig. 10 shows the displacements and
conformational changes occurring in the drug-binding residues. The
progressive changes in the conformation of these residues are indicated
using color coding (yellow, orange, gray, red and blue; yellow→ orange
corresponds to IO→ IIO transition; and orange→ gray→ red→ blue
corresponds to IIO→ OO transition). In the initial IO state the drug-
binding residueswere facing thehydrophobic cavity andhad anoptimal
conformation for substrate binding. As the simulation progressed from
IO to IIO state major displacements in the position of drug-binding
residues were noticed (Fig. 10). The structural transition from IIO to
OO state was themajor transition phase in which substantial conforma-
tional changes were noticed that would affect substrate binding. On
viewing the movement of these residues from the intracellular side
one can notice the residuesmove away from central axis, ﬁnally becom-
ing accessible from extracellular space. On observing the lateral view of
Fig. 7. Relative displacements in TM helices from IO to OO structural transition, initial IO conformation is represented as transparent blue ribbon. The adjacent distance versus time plot
shows the quantitative data of the corresponding TM helices during MTMD simulation. A, B and C represent displacements in TM7 and TM8, TM8and TM9, and TM11 and TM12,
respectively.
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that the TMs were accompanied by stretching movements. The TM
stretching was observed in all TMs but it was more pronounced in
case of TM4, −5, −6, −10, −11 and −12. Initially for L65 on
TM1 no signiﬁcant displacement was noticed but as the simulation
progresses from IIO toOO state the conformation of Leu residue changes
(orange→ gray→ red→ blue) and it faces away from hydrophobic
cavity. The S222 residue on TM4 clearly indicates that both stretching
and displacement was observed in TM4 but there was nomajor change
in the conformation of Ser residue. Similarmovements were noticed for
I306 on TM5. In case of L339, I340 and F343 on TM6 stretching move-
ments were coupled with major conformational changes of these
residues. The F728 residue on TM7, implicated in verapamil binding
showed substantial change in the orientation of phenyl ring, which
ﬁnally results in loss of stable interaction in OO state. The residues on
TM10 (I868 and G872) showed a large displacement and conformationchange, the Ile residue rotated by ~60° about vertical axis during the
course of transition from IIO to OO state. The F942 and T945 residues
on TM11 also showed a substantial displacement from the initial
position (yellow, IO state) as the structure transformed to OO state.
The F942 residue that forms hydrophobic interactions with substrate
showed a high degree of conformational change. In case of TM12,
more pronounced conformational changeswere observed. It was clearly
noticed that the residues L975, V981, V982 and A985, which faced the
hydrophobic cavity in IO state, rotated along the vertical axis and
attained a conformation in OO state that faced away from hydrophobic
cavity.
Cysteine scanning mutagenesis experiments performed by Loo and
Clarke [46,47] on IO state of P-gp structure provide important structural
information about the relative position of different parts of the TM
domains. The consistency of the IO state model with these studies has
been proven in our previous study [39]. The TM residues that have
Fig. 8. Relative displacements in TM helices from IO to OO structural transition, initial IO conformation is represented as transparent blue ribbon. The adjacent distance versus time plot
shows the quantitative data of the corresponding TM helices during MTMD simulation. A, B and c represent displacements in TM5 and TM11, TM6and TM9, and TM6 and TM12,
respectively.
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were shown to be located in close proximity in the modeled structure.
It was shown using in silico cysteine mutation that the residues of
TM2 (Val 133, Cys 137, Leu 138) and TM11 (Gly 939, Ala 935) had
inter-residue sulfur distance ranged from 3.3 Å to 5.2 Å, which was
within the prerequisite for disulﬁde bond formation. Similar inter-
actions were shown for TM8 (Phe 766, Phe 770, Phe 771, Gly 774, Phe
775) and TM5 (Gly 300, Ile 299, Ile 297, Asn 296, Ile 293) residues.
Loo and Clarke also established the experimental evidences impli-
cating that the transmembrane helices undergo relative movement
during ATP hydrolysis. In a series of cysteine cross-linking studies [48,
51,56] they showed that TM helices 11 and 12, 1 and 11, and 6 and 12
formed cysteine cross-linking only if the transporter turned via ATP
hydrolysis.
TheMTMD simulation trajectorieswere also analyzed to ﬁnd out the
movement of these TM helices and the residues implicated in cross-linking studies. The distance plot of these residues is shown in Fig. S8.
As the simulation progressed from IO to IIO conformation state, the
separation between these residues increased, maximum separation
was noticed at IIO state (at ~25 ns). Further, as the simulation
progressed from IIO to OO state, the transition showed minimum
separation between these residues and ﬁnally the separation increased
as the OO conformation state was achieved (at ~40 ns).
In a recent study, Loo and Clarke [58] provided biochemical evidence
that the structure of ICH2 in human P-gp resembles the crystal structure
of C. elegans, rather than that of mouse P-gp. The homology model of
human P-gp based on mouse P-gp erroneously predicts ICH2 residues
(residues Val253–Ala259 and Gly269–Lys272) as loop instead of α-
helices. The correct conformation of this region can be modeled using
C. elegans P-gp as template. The major difference between the two
models is the conserved salt bridge interaction between Glu256 and
Arg276, which is noticed only in C. elegans-based homology models.
Fig. 9. RMSD versus time plot of TM helices. (A) Plot of TM helices in TMD1, (B) Plot of TM
helices in TMD2.
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promote maturation of human P-gp.
The simulation was found consistent with the conserved salt bridge
interactions between Glu256 and Arg276. Fig. S9 shows the conserved
salt bridge interaction during MTMD simulation. It was noticed during
MTMD simulation that the conserved salt bridge interactions main-
tained from IO to IIO structural transition and disrupted when the
transition structure approached closer to OO state.
In another recent study, Loo and Clarke [57] performed drug rescue
of P-gp processing mutant experiments containing an arginine at each
position in TM5. The experiments help to identify positions of residues
facing the lipid or internal aqueous chamber. Correct orientation
of TM5 is critical for P-gp-drug binding in silico experiments, since
residues in TM5 (particularly I306) have been implicated to play a
crucial role in binding of drug substrates and coupling of drug binding
to activation of ATPase activity [68]. In their study, the authors showed
that the human P-gp homology models based on mouse P-gp predict
wrong orientation of I297, G300, A301, L304, A308, and A311 (actually
face lipid environment, but predicted to face drug-binding pocket),
and A295, S298, A302, L305, I306, and S309 (actually face drug-binding
pocket, but predicted to face lipid environment). The developed model
was found consistent with the position of these residues (Fig. S10).
Thus, corroborates the accuracy of structural modeling and suitability
of performing P-gp substrate/inhibitor binding studies on the developed
model.
In another recent experiment [69], Loo and Clarke tested the effects
of cross-linking mutant L175C (ICL1)/N820C (ICL3) to determine the
distance between N-terminal and C-terminal half of P-gp that showhigh or low ATPase activity. They observed that there was over 10 fold
increase in basal ATPase activity when L175C was linked to N820C
with cross-linkers predicted to span a distance of less than 20 Å, and
predicted that the ATPase activation switch appears to be turned on or
off when this distance is less than or greater than 20 Å, respectively. In
context to this study, here in our simulation studies we monitored the
distance between the L175 and N820 with respect to distance between
catalytic important residue E556 and E1201 and movement of NBDs (a
video in supplementary information, Movie 3 presents the motion of
these residues and NBDs during the course of simulation). It was
observed that as the distance between L175 and N820 reduced
from initial 29 Å to 20 Å the NBDs showed a twisting movement
and came closer. At a point where the distance between L175 and
N820 was 20 Å the distance between E556 and E1201 was 21 Å (initial,
at IO conformation was 39 Å). During this transition phase the NBDs
completed their twisting movement and were properly aligned, ready
to form a sandwich dimer thereafter, indicating the possible structural
rearrangement in P-gp that resulted in increased ATPase activity
when the distance between L175 and N820 decreased below 20 Å
separations. Similar type of NBD movement was also observed by
Wise [62].
Further, we performed in silico mutation analysis followed by
MTMD to get insights into the role of conserved apical interactions
between Phe335, Tyr310, Phe314 and Ile218, which is believed to be
responsible for the stability of IO conformation of P-gp structure [14,
70,71]. The Phe335 was located at the apex of the drug transport
pathway, making van der Waals interactions with Tyr310 and Phe314
in TM5, and Ile218 in TM4 (Fig. S11B). Interestingly, it was noticed
during MTMD simulation that the movement of NBDs and formation
of their catalytic dyadduringOO catalytic state, are somehowcorrelated
to these conserved apical interactions in P-gp structure in IO catalytic
state. To verify the role of these interactions in P-gp catalytic transfor-
mation, these residues were mutated to alanine (Fig. S11C). As a result
the binding interactions were disrupted. The mutated structures were
again subjected to MTMD simulation. It was observed that the move-
ment of NBDs changed substantially. Figs. S11D and S11E show the
movement of conserved Glu residues of NBD before and after mutation,
respectively. The twistingmovement of NBDs became less pronounced.
The graph in Fig. S11F clearly shows that the separation between the
Glu residues increased aftermutation. Thus, resulting into the distortion
of catalytic dyad and may result in loss of activity.
Moreover, the hydrophobic substrate gates were also noticed during
the MTMD simulation. These gates were noticed during IO to IIO tran-
sition of P-gp structure. The gates were noticed in the hydrophobic
membrane embedded region of P-gp. A hydrophobic gate with ~18 Å
in diameter was noticed between TM1 and TM2 (constituted by resi-
dues Ile 60, Val 125 and Ala 128) and another of ~14 Å in diameter
was noticed between TM7 and TM9 (constituted by residues Ala 718,
Gly 722, Ala 834 and Ala 841) (Fig. S12). Similar hydrophobic gates
between TM1 and TM2 were also noticed by Shintre et al. [10], though
the study does not mention any hydrophobic portal between TM7 and
TM9. It was noticed during the simulation that the residues Ala 718,
Gly 722, Ala 834 and Ala 841 that formed a tight packing close to lipid
bilayer in IO conformation gradually move away making an access
portal to the cavity of P-gp. Similar transition was also noticed between
residues of TM1 and TM2.
3.3. Induced ﬁt docking and MTMD analysis of substrates/inhibitors
This part of study was conducted with an objective to address
following queries: (i) to ﬁgure out is there different binding site for
substrate and inhibitor, (ii) differences in molecular interactions of
substrate and inhibitor, (iii) conformational changes in the key residues
involved in ligand binding and how these conformational changes
render instability in ligandbinding, and (iv) efﬂuxmotion path followed
by substrates and inhibitors. To confer these objectives, eight substrates
Fig. 10. Conformational changes and displacements observed in drug-binding residues during IO to OO structural transition of P-gp. The ﬁgure shows intracellular view of the initial IO
conformation state, represented as transparent ribbon (NBDs are not shown). The progressive changes in the conformation of drug-binding residues (magniﬁed lateral view) are indicated
using color coding (yellow, orange, gray, red and blue; yellow→ orange correspond to IO→ IIO transition; and orange→ gray→ red→ blue correspond to IIO→ OO transition).
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developed human P-gp homology model. The best docked poses of
substrates and inhibitors were then subjected to multi-targeted
molecular dynamics to investigate the changes in molecular interac-
tions during the catalytic transition of P-gp.
The IFD protocol was validated as mentioned in the previous work
[39] (data not shown). The co-crystallized structure (OSA) was docked
into C. elegans crystal structure. Interactions and conformation of co-
crystallized ligand similar to crystal structure were generated by IFD,
forming H-bonding interactions with Thr 1025 and Thr 1028, and
having an atomic RMSD of 0.68 Å. IFD in human P-gp homology
model also showed interaction with homologous residues. Further, IFD
studies of knownP-gp substrates and inhibitors (listed in supplementary
information Table S1)were performed on human P-gp homologymodel.
The in-depth investigation of IFD poses showed that the substrates
and inhibitors formed stable binding interactions with the experimen-
tally reported residues. The ﬁrst row of each entry (labeled as initial)
in Table S4 and S5 enlists the residues thatwere in close contactwith re-
spective inhibitor and substrate. 3D interaction images of each substrate
and inhibitor are provided in Figs. S13–S25. Each substrate and inhibitor
formed stable binding interactions with at least three of the experimen-
tally reported residues except nifedipine. The docking of co-crystallized
substrate and the stable binding interactions of test compounds well
correlated with the experimental studies [42–45,49,52,63,64,67]. Thus,
the results strongly supported the validity of docking experiments and
structural modeling of human P-gp.
In context to ﬁrst objective no separate binding sites were observed
for substrate and inhibitor. Two binding sites were noticed viz. one
accommodated between TM4, TM5, TM6 TM7, TM8 TM9 and TM12(site 1) (Fig. 11A) and other between TM1, TM2, TM3, TM6, TM10,
TM11 and TM12 (site 2) (Fig. 11B). Both sites had TM6 and TM12 in
common, which have been proved to be involved in ligand binding
through experimental studies [45,49]. Both substrate and inhibitor
showed binding tendency in either of the active site. The test substrate
etoposide occupied stable docked conformation in site 1, whereas
the other test substrate showed stable binding conformation at site 2
(substrates/inhibitors occupying site 1would bewritten in italics further
in text for easy distinction). However, in case of inhibitor about half
of the inhibitors occupied site 1 (biricodar, tamoxifen, tariquidar and
verapamil) and the other half occupied the site 2 (laniquidar, nifedipine,
reserpine and ketoconazole). Tables S4 and S5 clearly indicate that most
of the substrates and inhibitors have common interacting residues.
Analyses concerning the difference in molecular interactions between
substrate and inhibitor, each compound had varied interactions
depending upon its molecular structure and property, but no clear
distinction between the interactions of substrates and inhibitors
was noticed. Hydrophobic interactionswere predominantly responsible
for stable binding in most of the cases.
Moreover, as discussed in a study conducted by Loo and Clarke [72]
binding of substrate induces conformational changes in TM helices. In
IFD experiments substrate and inhibitor induced conformational changes
in the residues of TM helices were noticed. For instance, doxorubicin
showed conformational changes in residues of TM helices (Fig. S26A).
The residues P350 (TM6) and S993 (TM12) were reported to cross link
in the cysteine mutagenesis experiments, the distance between these
residues increased in response to doxorubicin binding. The residue
V991 (TM12) shown to cross link with P350 due to substrate
(colchicines/demecolcine) induced conformational changes, was
Fig. 11. The two binding sites observed during induced ﬁt docking studies. (A) Site 1,
accommodated between TM4, TM5, TM6 TM7, TM8 TM9 and TM12. (B) Site 2,
accommodated between TM1, TM2, TM3, TM6, TM10, TM11 and TM12.
Fig. 12.RMSDplot of compounds during the course ofMTMDsimulation. (A) RMSDplot of
inhibitors (B) RMSD plot of substrates.
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indicating the possible reason of cross linking observed due to substrate
induced conformational changes. Similar conformational changes
were observed for all anthracycline compounds (Fig. S26B). The study
reported, no cross linkingwas observed in anymutants in case of verap-
amil and vinblastine, however conformational changes in residueswere
observed in response to verapamil and vinblastine binding. The possible
reason why cross-linking was not observed could be; (i) in case of
vinblastine it was observed that the residues V991 (TM12) and S993
(TM12) both moved away from P350 (Fig. S26C) and (ii) in case of
verapamil it was observed that verapamil binds at site 1, which do not
involve TM11, and its binding induced major conformational changes
in the residues of TM5, TM6 and TM12 (Fig. S26D), moreover the
residues P350 and S993 were not in the vicinity of verapamil binding.
MTMD studies of stable binding poses of substrates and inhibitors
were further carried out to analyze the conformational changes in the
residues forming stable binding interactions. In depth analyses of con-
formational changes in drug-binding residues were carried out during
the P-gp structure transition from IO to OO catalytic state. Each residue
was closely observed to ﬁnd out the changes in molecular interactions
that destabilized the stable binding of substrates and inhibitors. Also,
to elucidate the path followed by substrate and inhibitor, while they
are efﬂuxed out, and any possible distinction between the two, which
differentiate them as substrate and inhibitor. However, the timescale
of simulation was insufﬁcient to trace out the actual motion path of
substrate and inhibitor; we observed a clear distinction between
the molecular interactions of substrate and inhibitor. On analyses ofMTMD trajectories it was observed that most of the residues, which
have been implicated in ligand binding, face away from the transloca-
tion pathway as the structure approaches closer to OO catalytic state.
These conformational changes in the drug-binding residues completely
destabilized the stable hydrophobic interactions essential for ligand
binding. As the transition in P-gp structure proceeds from IO to OO
state, the lining of the drug translocation pathway gradually changes
from highly hydrophobic to less hydrophobic and ﬁnally to hydrophilic.
The RMSD plot of each substrate and inhibitor (Fig. 12) clearly indicates
that as the P-gp structure enters the IIO to OO transition phase there is a
noticeable increase in the RMSD of substrates and inhibitors. It was
observed that most of the substrates get destabilized due the confor-
mational changes in the residues lining the drug-binding pocket and
dislocates from actual binding site. In Fig. 12B the increase in RMSD
corresponds to the dislocation of substrate from the drug-binding
site. Similar kind of destabilization was also noticed in inhibitors
(Fig. 12A), however the changes in their interactions were different
from substrates. Though the inhibitors also dislocated from actual
binding site, they seemed to be “sticky” i.e. they showed a tendency
to retain stable binding interaction with at least one of the drug-
binding residue during the catalytic transition from IO to OO state.
Table S4 lists the residues in close contact during each nanosecond
of simulation, residue represented in bold (at least one is the drug-
binding residue implicated in experimental studies) maintain close
contact during all phases of simulation. The table clearly shows that
unlike substrate, each inhibitor maintained a close contact with either
of the drug-binding residue during all phases of the catalytic transition.
2894 R. Prajapati, A.T. Sangamwar / Biochimica et Biophysica Acta 1838 (2014) 2882–2898Biricodar tends to retain its hydrophobic interaction with I306, A342
and F343, ligand binding residues implicated in experimental studies,
during the all transition phase of P-gp structure from IO to OO state. It
also maintained close contact with F303 and Y310. Laniquidar main-
tained close contact with I868. Reserpine maintained its hydrophobic
interactions with F942 and A985. Tariquidarmaintained binding inter-
actionswith I306 and F343. Tamoxifenmaintained hydrophobic interac-
tions with L399, F343 and F728. Ketoconazole retained its interactions
with T941 and T945. Verapamil maintained hydrophobic interactions
with I306, L399, A342, F343 and V982. In contrast, the substrates
lost their stable binding interactions after IIO catalytic state and get
destabilized, and dislocates from actual binding site. Snapshots of inter-
action of each substrate and inhibitor during the course of MTMD
simulation is provided in supplementary information Figs. S13–S25.
The four anthracycline compounds occupied the same binding site
(site 2) having almost similar molecular interactions. The change in
their RMSD pattern (Fig. 12B) was also observed to be similar as the
most of interacting residueswere common, the conformational changes
in the interacting residues (Table S4) during IIO to OO transition resulted
in sudden increase in the RMSD as the compound losesmost of its stable
interactions. Verapamil and doxorubicin as a representative of inhibitor
and substrate respectively are discussed in detail.
Initially in IO state, verapamil showed stable binding interactions at
site 1. Fig. 13 shows the gradual changes in conformation and position
of residues that formed close contact with verapamil. The close contact
residues are shown as licorice (residues implicated in drug binding of P-Fig. 13. Changes inmolecular interactions of verapamil observed duringMTMDsimulation; A, B,
conformation state, respectively. The magniﬁed images of encircled region are shown as I, II, IIgp) andCPK representations.Verapamil showedhydrophobic interactions
with L339, Y310, F343 and I306, andπ–π interactionwith F303, initially in
IO state (Fig. 13A). As the simulation progressed from IO to OO conforma-
tion state these interactions changed gradually. When the structure ac-
quired a conformation close to IIO state (Fig. 13B), verapamil loses π–π
interaction with F303. Fig. 13C represents a transition structure noticed
after IIO state (at the beginning of IIO to OO transition), clearly shows
that most of the close contact residues (CPK, representation) moved
away from verapamil, losing their close contacts. However, verapamil,
though in different conformation maintained hydrophobic interactions
with drug-binding residues L339, F303 and Y307, and showed close
contact with Y310 and F343. Finally, in OO state (Fig. 13D) verapamil
showed conformational change, but retained its hydrophobic interac-
tionswith drug-binding residues. A video showing these conformation-
al changes in presented in supplementary information (Movie 4).
In contrast, doxorubicin showed stable binding interactions at site 2
in IO state and formed hydrophobic interactions with L65, F343, F942
and M986 (Fig. 14A). Doxorubicin maintained these stable interac-
tions till IIO state (Fig. 14B). As the simulation progressed from
IIO to OO state, doxorubicin gradually moved out of the binding
pocket losing the stable binding interactions (Fig. 14C). Finally, in
OO state (Fig. 14D) both drug-binding residues and the residues
in close contact showed maximum separation with doxorubicin,
destabilizing the stable binding of doxorubicin. A video showing
these conformational changes in presented in supplementary infor-
mation (Movie 5).C andD represent the P-gp transition structures initial IO, at starting of IIO, after IIO andOO
I and IV.
2895R. Prajapati, A.T. Sangamwar / Biochimica et Biophysica Acta 1838 (2014) 2882–28983.4. Insights into P-gp translocation mechanism
TheMTMD technique used here to study the structural changes in P-
gp structure as it transforms from IO to OO catalytic state provided valu-
able insights into the P-gp efﬂux mechanism. The TMD analyses, details
of NBD movements, and measurements of ICH movement and rotation
in ball and socket joint of NBD provide a clear picture how P-gp struc-
ture undergoes a large body of structural changes from drug-binding
pocket exposed to intracellular space to drug-binding pocket exposed
to extracellular space. Also, the speciﬁc pattern of opening of P-gp struc-
ture to the extracellular space is due to the speciﬁc arrangement pattern
of TM helices in TMDs.
The ICHs were noticed as main connecting link between TMDs and
NBDs and could be regarded as motion transformers that transform
the twisting and translatory motion of NBDs to pushing motion. These
motion transformers are vital link for P-gp efﬂux mechanism. During
the transition from IO to IIO state the NBDs move closer, the ICHs also
move in concert and the translatory shift of NBDs is transmitted to
TMDs via ICHs as a pushing motion. ICH1 connected to TM2 and TM3,
pushes these TMs as it moves from IO to OO conformation state; how-
ever the stretching of both TMs is in opposite direction. This is due to
the arrangement of TMs in TMD1. TM3 is connected to TM4 through a
short extracellular loop, which in turn is connected to ICH2 embedded
in NBD2. Thus, the movement of TM3 is also affected by the movement
of TM4. TM4 and TM5 are connected to ICH2 and shows stretching due
to a push exerted by ICH2 in response to NBD2 movement. Moreover,
TM5 connected to TM6 (has physical contact with NBD1), through an
extracellular loop, which intersect the inverted V formed by TM3 and
TM4. This arrangement results into the movement of TM3, −4, −5Fig. 14. Changes inmolecular interactions of doxorubicin observed duringMTMD simulation; A
OO conformation state, respectively. The magniﬁed images of encircled region are shown as I,and−6 toward the same side. So, if one observes the structural change
in TMD1 from a lateral view with both NBD overlapping each other, it
could be clearly observed that the TM3,−4,−5 and−6 moves in left
directions and TM1 and TM2 moves in right direction. Interestingly,
the gradual pushing motion of ICH2 on TM4 and TM5 during transition
from IO to OO state gradually straightened these helices and ﬁnally they
attained a bow-like structure in the OO conformation state. However,
the curvature was more pronounced in the case of TM4. Similar type
of rearrangements was observed in TMD2 in response to pushing
force exerted by ICH3 and ICH4, while showing a concerted movement
with NBD1 andNBD2. In TMD2, TM10 and TM11 showed a curved bow-
like structure in ﬁnal OO conformational state, TM10 showedmore pro-
nounced curvature. These gradual rearrangements in TMD1 and TMD2
from IO to IIO, and then to OO state ﬁnally resulted in the opening of
P-gp structure toward the extracellular space making the drug-
binding region solvent accessible from the extracellular side.
Moreover, the movements of ICHs and the corresponding move-
ments in TM helices observed in MTMD simulation provide a good ex-
planation for the inactivation of P-gp on cross-linking ICH2 and ICH3,
mentioned in a recent experimental study [73]. In this experiment Loo
and Clarke cross-linked A259C (ICH2) andW803C (ICH3) that resulted
in loss of P-gp ATPase activity. The role of ICHdiscussed above and in the
previous section clearly explains that the cross-linkingwill inhibited the
conformation changes in TM4, TM5, TM8 and TM9 in response to ICH2
and ICH3 movement, which possibly explain the reason of P-gp in-
activation. The study also discusses the importance of Y1087, mutation
in which inhibited maturation of P-gp. In our simulation studies Y1087
was found to form conserved salt-bridge interactions with Arg
262 (ICH2) and Asp 805 (ICH3) in IO conformation, which gradually, B, C and D represent the P-gp transition structures initial IO, at starting of IIO, after IIO and
II, III and IV.
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not only abolish conserved salt-bridge interaction but also inhibit the
related conformational changes in ICH2 and ICH3.
The quantitative data relating movements of TM and ICH discussed
in the previous section well correlates with the mechanism hypo-
thesized above on the basis of MTMD experiments. A negligible change
was observed in the distance between TM1 and TM2 that indicates both
the TMs move in same direction. However, the straightening of TM2
resulted into the conformational change in the extracellular loop
connecting TM1 and TM2. This loop is analogous to a lid that covers
the extracellular opening of the P-gp transporter. As the TM2
straightens during IO to OO transition this loop gradually moves to
open the extracellular covering. The large change noticed in distance
between TM2 and TM3 is reasonable as both TMs move in opposite
direction. The angular twist of ~20 Å observed in ICH1 could be
correlated to provide initial opposite directional momentum to
TM2 and TM3 in response to pushing exerted by ICH1. The pro-
minent change in the distance between TM4 and TM10, TM5 and
TM11, and TM6 and TM9 was observed as they moved in opposite
direction. The higher RMSD of TM4 and the twist in ICH2 could be
correlated to higher curvature observed for TM4. The higher RMSD
of TM1 as compared to TM7 was attributed to higher conformational
change in extracellular loop connecting TM1 and TM2.
The MTMD simulations of substrates and inhibitors gave insights
into the structural transition of TM helices. During IO to OO transition
the TM helices move away accompanied by conformational changes in
the drug-binding residues, in response to these conformational changes
both substrate and inhibitor were dislocate from their actual binding
site, but the inhibitors seemed to maintain the binding interactions
with some of the drug-binding residues. The observed results does not
state any quantitative differentiation in binding afﬁnity of substrate or
inhibitor, however it could be proposed that in actual biological mecha-
nism inhibitors may have a tendency to inhibit certain conformational
changes in these drug-binding residues and thus hindering the move-
ment of TM helices essential for catalytic efﬂux. Also, it could be inter-
preted that the inhibitors may have higher binding afﬁnity then
substrates.
The translocation mechanism of P-gp proposed here on the basis of
MTMD experiments on P-gp structures and large number of MTMD
experiments conducted with known P-gp substrate and inhibitors
presents an overall picture of P-gp translocation mechanism.
The study gives substantial detailed into reaarangements of TMDs,
importance of ICHs and interactions of inhibitors during P-gp catalytic
providing testable hypotheses for future studies.
4. Conclusions
The selected template structures for modeling studies had a large
difference between their NBDs representing different catalytic state of
P-gp. The generated human P-gp models in three different catalytic
states, using C. elegans, human mitochondrial and Sav1866 P-gp as
templates showed very few geometric constraints. Ramachandran and
errat plot indicated good reliability of generated models. The subse-
quent embedding of model in lipid bilayer followed by 50 ns MD
equilibration further reﬁned the overall geometry of the structures.
Furthermore, the models showed good consistency with experimental
studies, providing reasonable structures to perform ligand binding
interaction studies.
The MTMD technique used here gave valuable insights into the P-gp
efﬂuxmechanism. The IO conformational statewas taken as the starting
structure for MTMD studies, as this structural state was well validated
against experimental data. Moreover, the IO to OO structural transition
could be better utilized to study substrate/inhibitor binding interac-
tions, as the substrate and inhibitor bind stably in IO conformation of
P-gp and later get destabilized in OO conformational state. The MTMD
simulation from IO to OO state incurred a better understanding of theNBD movements, role of ICHs and TMD rearrangements during the
P-gp efﬂux cycle. The IO to OO structural change of P-gp is contributed
by both twisting and translatory motion of NBDs. The IO to IIO state
change showed the initial twisting motion of NBDs, while IIO to OO
state transition showed translatory motion where the NBDs approach
each other and dimerize to form catalytic dyad. ICHs, which were well
adjusted into the grooves of NBDs forming a ball and socket-like joint,
showed concerted movement with NBDs. These ICHs were observed
as motion transformers that transform rotatory and translatory motion
of NBDs to a pushingmotion, resulting into the rearrangement of TMDs.
Moving along with NBDs, ICHs also showed rotatory motion into the
grooves of NBDs as governed by conserved interactions. Coupled with
rotatory motion the ICHs pushed 8 out of 12 TM helices (2, 3, 4, 5, 8,
9, 10 and 11), predominant pushing force was exerted on TM4–TM5,
and TM10–TM11 via ICH2 and ICH4, respectively. In response to NBD
and ICHmovement, the TMDs showed a dramatic rearrangement, ﬁnal-
ly resulting into the opening of drug-binding region to extracellular
space. A speciﬁc pattern of opening of TMDs was due to the topological
arrangement of TMhelices. The diametric stretching of TM2 and TM3 in
response to ICH1 movement was observed on account of the arrange-
ment of TM3, 4 and 6, and bent topology of TM3helix. Identical arrange-
ment of TM8, 9 and 12 resulted into the diametric stretching of TM8 and
TM9. The stretching TM2 also resulted into the conformational change
in extracellular loop connecting TM1 and TM2. Prominent straightening
of TM4, 5, 10 and 11 observed during IO to OO structural transition of
P-gp in response to ICH2 and ICH4movements, respectively, majorly
contributed to TMD rearrangement.
The study provides signiﬁcant details of conformational changes
in the drug-binding residues that occurred from IO state, where drug-
binding pocket is accessible from intracellular space to OO state,
where drug-binding region becomes accessible from extracellular
space. The simulation clearly depicted that the drug binding-residues
acquired conformation that face away from drug-binding pocket as
the P-gp structure approached the OO state. Alongwith conformational
changes, these residues also showed displacements from their initial
position, gradually moving apart from central axis. The conformational
changes in drug-binding residues and their corresponding movements
distorted the binding site(s) and represented a clear picture how a
stably binding ligand possibly get destabilized in OO conformation
state. Furthermore, the consistency of developed model and MTMD
simulations with experimental data provide strong evidence toward
the validity and reliability of the results presented here.
Here, using MTMD studies we reported the interaction studies of
P-gp substrate and inhibitor during the P-gp efﬂux cycle. The reported
study gives an incisive understanding of the P-gp substrate and inhibi-
tor molecular interactions. No distinct site for substrate and inhibitor
binding was noticed, however, substantial difference in substrate and
inhibitor binding interaction was noticed during the simulation from
IO to OO state. The results clearly showed how substrate binding in
the active site of P-gp gradually gets destabilized as the structure
transform from IO to OO state. The results also showed a clear distinc-
tion between substrate and inhibitor interactions during P-gp catalytic
cycle. The substrates loose their stable binding interactions and dislocate
from actual binding site as the conformation of drug-binding residues
gradually changed from IO to OO state, whereas the inhibitors main-
tained stable interactionswith drug-binding residues, posing possibility
of inhibition of the conformational change in P-gp structure. The resi-
dues F303, I306, F343, F728, I868, F942, T945 and A985 were found
crucial for inhibitor interactions. The inhibitors in docking and MTMD
experiments showed stable binding interactions with at least one of
these residues depending on the binding site they occupied.
Apart from mechanistic insights drawn from MTMD simulations
here, further MD simulation experiments would be required to recon-
cile in silico studies with experimental studies. For instance, the study
here considered lowest energy docked pose in MTMD studies, however
a ligand could bind in multiple orientations. It has been reported that
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occupy different regions in the common drug-binding pocket [74].
Another set of simulation needs to be carried out to study how binding
of two substrates will affect themovements and conformational chang-
es in TM helices. Further, the MTMD technique could not be efﬁciently
utilized to study the difference between substrate and inhibitor induced
conformational changes in NBDs [75]. There are also biochemical evi-
dences that the binding of nucleotide at NBDs induces conformational
changes in TMDs [76]. Very long atomistic simulationswould be further
required to accommodate in silico experiments with these biochemical
evidences.
The mechanistic picture of translocation of P-gp presented here,
usingMTMD studies gave sufﬁcient details into conformational changes
in drug-binding region, role of ICHs and topological arrangements of TM
helices in P-gp translocation, and quantitative shifts TM helices pro-




NBD nucleotide binding domain
ICH intracellular coupling helix
MTMD multi-targeted molecular dynamics
IFD induced ﬁt docking
TM trans-membrane.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2014.07.018.
Acknowledgement
The authors are thankful to the Department of Biotechnology
(DBT), New Delhi (Grant number is BT/PR/14979/BID/07/353/
2010), for ﬁnancial support.
References
[1] R.L. Juliano, V. Ling, A surface glycoprotein modulating drug permeability in Chinese
hamster ovary cell mutants, Biochim. Biophys. Acta 455 (1976) 152–162.
[2] H.S.L. Chan, G. Haddad, P.S. Thorner, G. DeBoer, Y.P. Lin, N. Ondrusek, H. Yeger, V.
Ling, P-glycoprotein expression as a predictor of the outcome of therapy for
neuroblastoma, N. Engl. J. Med. 325 (1991) 1608–1614.
[3] P.D.W. Eckford, F.J. Sharom, ABC efﬂux pump-based resistance to chemotherapy
drugs, Chem. Rev. 109 (2009) 2989–3011.
[4] M.M. Gottesman, I. Pastan, The multidrug transporter, a double-edged sword, J. Biol.
Chem. 263 (1988) 12163–12166.
[5] M. Hennessy, J.P. Spiers, A primer on the mechanics of P-glycoprotein the multidrug
transporter, Pharmacol. Res. 55 (2007) 1–15.
[6] G. Szakács, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, M.M. Gottesman, Targeting
multidrug resistance in cancer, Nat. Rev. Drug Discovery 5 (2006) 219–234.
[7] C.F. Higgins, R. Callaghan, K.J. Linton, M.F. Rosenberg, R.C. Ford, Structure of the
multidrug resistance P-glycoprotein, Semin. Cancer Biol. 8 (1997) 135–142.
[8] P.M. Jones, A.M. George, Subunit interactions in ABC transporters: towards a
functional architecture, FEMS Microbiol. Lett. 179 (1999) 187–202.
[9] F.J. Sharom, The P-glycoprotein efﬂux pump: how does it transport drugs? J. Membr.
Biol. 160 (1997) 161–175.
[10] C.A. Shintre, A.C.W. Pike, Q. Li, J.-I. Kim, A.J. Barr, S. Goubin, L. Shrestha, J. Yang, G.
Berridge, J. Ross, P.J. Stansfeld, M.S.P. Sansom, A.M. Edwards, C. Bountra, B.D.
Marsden, F. von Delft, A.N. Bullock, O. Gileadi, N.A. Burgess-Brown, E.P. Carpenter,
Structures of ABCB10, a human ATP-binding cassette transporter in apo- and
nucleotide-bound states, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 9710–9715.
[11] R.J.P. Dawson, K.P. Locher, Structure of a bacterial multidrug ABC transporter, Nature
443 (2006) 180–185.
[12] A. Ward, C.L. Reyes, J. Yu, C.B. Roth, G. Chang, Flexibility in the ABC transporter MsbA:
alternating access with a twist, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19005–19010.
[13] S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q.
Zhang, I.L. Urbatsch, G. Chang, Structure of P-glycoprotein reveals a molecular basis
for poly-speciﬁc drug binding, Science 323 (2009) 1718–1722.
[14] M.S. Jin, M.L. Oldham, Q. Zhang, J. Chen, Crystal structure of the multidrug transport-
er P-glycoprotein from Caenorhabditis elegans, Nature 490 (2012) 566–569.
[15] J. Li, K.F. Jaimes, S.G. Aller, Reﬁned structures of mouse P-glycoprotein, Protein Sci.
(23) (2014) 34–46.[16] J.D. Campbell, S.S. Deol, F.M. Ashcroft, I.D. Kerr, M.S.P. Sansom, Nucleotide-
dependent conformational changes in HisP: molecular dynamics simulations of an
ABC transporter nucleotide-binding domain, Biophys. J. 87 (2004) 3703–3715.
[17] J.D. Campbell, M.S.P. Sansom, Nucleotide binding to the homodimeric MJ0796
protein: a computational study of a prokaryotic ABC transporter NBD dimer, FEBS
Lett. 579 (2005) 4193–4199.
[18] J.M. Damas, A.S.F. Oliveira, A.M. Baptista, C.M. Soares, Structural consequences of
ATP hydrolysis on the ABC transporter NBD dimer: molecular dynamics studies of
HlyB, Protein Sci. 20 (2011) 1220–1230.
[19] P.M. Jones, A.M. George, Mechanism of ABC transporters: a molecular dynamics
simulation of a well characterized nucleotide-binding subunit, Proc. Natl. Acad.
Sci. U. S. A. 99 (2002) 12639–12644.
[20] P.M. Jones, A.M.George, TheABC transporter structure andmechanism: perspectives
on recent research, Cell. Mol. Life Sci. 61 (2004) 682–699.
[21] P.M. Jones, A.M. George, Nucleotide-dependent allostery within the ABC transporter
ATP-binding cassette, J. Biol. Chem. 282 (2007) 22793–22803.
[22] P.M. Jones, A.M.George, Opening of theADP-bound active site in the ABC transporter
ATPase dimer: evidence for a constant contact, alternating sites model for the
catalytic cycle, Proteins Struct. Funct. Genet. 75 (2009) 387–396.
[23] P.M. Jones, A.M. George, Molecular-dynamics simulations of the ATP/apo state of a
multidrug ATP-binding cassette transporter provide a structural and mechanistic
basis for the asymmetric occluded state, Biophys. J. 100 (2011) 3025–3034.
[24] A.S.F. Oliveira, A.M. Baptista, C.M. Soares, Insights into the molecular mechanism of
an ABC transporter: conformational changes in the NBD dimer of MJ0796, J. Phys.
Chem. B 114 (2010) 5486–5496.
[25] E.O. Oloo, E.Y. Fung, D.P. Tieleman, The dynamics of the MgATP-driven closure of
MalK, the energy-transducing subunit of the maltose ABC transporter, J. Biol.
Chem. 281 (2006) 28397–28407.
[26] P.C. Wen, E. Tajkhorshid, Dimer opening of the nucleotide binding domains of ABC
transporters after ATP hydrolysis, Biophys. J. 95 (2008) 5100–5110.
[27] J.P. Becker, G. Depret, F. Van Bambeke, P.M. Tulkens, M. Pravost, Molecularmodels of
human P-glycoprotein in two different catalytic states, BMC Struct. Biol. 9 (2009) 3.
[28] A. Ivetac, J.D. Campbell, M.S.P. Sansom, Dynamics and function in a bacterial ABC
transporter: simulation studies of theBtuCDF systemand its components, Biochemistry
46 (2007) 2767–2778.
[29] C. Kandt, D.P. Tieleman, Holo-BtuF stabilizes the open conformation of the vitamin
B12 ABC transporter BtuCD, Proteins Struct. Funct. Genet. 78 (2010) 738–753.
[30] A.S. Oliveira, A.M. Baptista, C.M. Soares, Conformational changes induced by ATP-
hydrolysis in an ABC transporter: a molecular dynamics study of the Sav 1866
exporter, Proteins Struct. Funct. Genet. 79 (2011) 1977–1990.
[31] E.O. Oloo, D.P. Tieleman, Conformational transitions induced by the binding of
MgATP to the vitamin B12 ATP-binding cassette (ABC) transporter BtuCD, J. Biol.
Chem. 279 (2004) 45013–45019.
[32] J. Sonne, C. Kandt, G.H. Peters, F.Y. Hansen, M.Ã. Jensen, D.P. Tieleman, Simulation of
the coupling between nucleotide binding and transmembrane domains in the ATP
binding cassette transporter BtuCD, Biophys. J. 92 (2007) 2727–2734.
[33] J.F. St-Pierre, A. Bunker, T. Rog, M. Karttunen, N. Mousseau, Molecular dynamics
simulations of the bacterial ABC transporter SAV1866 in the closed form, J. Phys.
Chem. B 116 (2012) 2934–2942.
[34] T.G. Sun, M. Liu, W.Z. Chen, C.X. Wang, Molecular dynamics simulation of the trans-
membrane subunit of BtuCD in the lipid bilayer, Sci. China Life Sci. 53 (2010) 620–630.
[35] P.C. Wen, E. Tajkhorshid, Conformational coupling of the nucleotide-binding and the
transmembrane domains in ABC transporters, Biophys. J. 101 (2011) 680–690.
[36] J.W. Weng, K.N. Fan, W.N. Wang, The conformational transition pathway of ATP
binding cassette transporter MsbA revealed by atomistic simulations, J. Biol.
Chem. 285 (2010) 3053.
[37] M.L. O'Mara, A.E. Mark, The effect of environment on the structure of a membrane
protein: P-glycoprotein under physiological conditions, J. Chem. Theory Comput. 8
(2012) 3964–3976.
[38] R.J. Ferreira, M.-J.U. Ferreira, D.J.V.A. dos Santos, Insights on P-glycoprotein's efﬂux
mechanism obtained by molecular dynamics simulations, J. Chem. Theory Comput.
8 (2012) 1853–1864.
[39] R. Prajapati, U. Singh, A. Patil, K.S. Khomane, P. Bagul, A.K. Bansal, A.T. Sangamwar, In
silico model for P-glycoprotein substrate prediction: insights from molecular
dynamics and in vitro studies, J. Comput. Aided Mol. Des 27 (2013) 347–363.
[40] Schrödinger Suite 2009 Induced Fit Docking protocol; Glide version 5.5, Prime
version 2.1, Schrödinger, LLC, New York, NY, 2009.
[41] W. Sherman, H.S. Beard, R. Farid, Use of an induced ﬁt receptor structure in virtual
screening, Chem. Biol. Drug Des. 67 (2006) 83–84.
[42] T.W. Loo, M.C. Bartlett, D.M. Clarke, Transmembrane segment 1 of human P-
glycoprotein contributes to the drug-binding pocket, Biochem. J. 396 (2006)
537–545.
[43] T.W. Loo, M.C. Bartlett, D.M. Clarke, Transmembrane segment 7 of human P-
glycoprotein forms part of the drug-binding pocket, Biochem. J. 399 (2006) 351–359.
[44] T.W. Loo, D.M. Clarke, Identiﬁcation of residues in the drug-binding site of human P-
glycoprotein using a thiol-reactive substrate, J. Biol. Chem. 272 (1997) 31945–31948.
[45] T.W. Loo, D.M. Clarke, Identiﬁcation of residues within the drug-binding domain
of the human multidrug resistance P-glycoprotein by cysteine-scanning
mutagenesis and reaction with dibromobimane, J. Biol. Chem. 275 (2000)
39272–39278.
[46] T.W. Loo, M.C. Bartlett, D.M. Clarke, Disulﬁde cross-linking analysis shows that
transmembrane segments 5 and 8 of human P-glycoprotein are close together on
the cytoplasmic side of the membrane, J. Biol. Chem. 279 (2004) 7692–7697.
[47] T.W. Loo, M.C. Bartlett, D.M. Clarke, Val133 and Cys137 in transmembrane segment
2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-
glycoprotein, J. Biol. Chem. 279 (2004) 18232–18238.
2898 R. Prajapati, A.T. Sangamwar / Biochimica et Biophysica Acta 1838 (2014) 2882–2898[48] T.W. Loo, M.C. Bartlett, D.M. Clarke, ATP hydrolysis promotes interactions between
the extracellular ends of transmembrane segments 1 and 11 of human multidrug
resistance P-glycoprotein, Biochemistry 44 (2005) 10250–10258.
[49] T.W. Loo, M.C. Bartlett, D.M. Clarke, Identiﬁcation of residues in the drug translocation
pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis,
J. Biol. Chem. 284 (2009) 24074–24087.
[50] T.W. Loo, M.C. Bartlett, D.M. Clarke, Human P-glycoprotein contains a greasy
ball-and-socket joint at the second transmission interface, J. Biol. Chem. 288
(2013) 20326–20333.
[51] T.W. Loo, D.M. Clarke, Drug-stimulated ATPase activity of human P-glycoprotein
requires movement between transmembrane segments 6 and 12, J. Biol. Chem.
272 (1997) 20986–20989.
[52] T.W. Loo, D.M. Clarke, Identiﬁcation of residues in the drug-binding domain of
human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-
scanning mutagenesis and inhibition by dibromobimane, J. Biol. Chem. 274
(1999) 35388–35392.
[53] T.W. Loo, D.M. Clarke, The packing of the transmembrane segments of human mul-
tidrug resistance P-glycoprotein is revealed by disulﬁde cross-linking analysis, J.
Biol. Chem. 275 (2000) 5253–5256.
[54] T.W. Loo, D.M. Clarke, Determining the dimensions of the drug-binding domain of
human P-glycoprotein using thiol cross-linking compounds as molecular rulers, J.
Biol. Chem. 276 (2001) 36877–36880.
[55] T.W. Loo, D.M. Clarke, Deﬁning thedrug-binding site in thehumanmultidrug resistance
P-glycoprotein using a methanethiosulfonate analog of verapamil MTS-verapamil, J.
Biol. Chem. 276 (2001) 14972–14979.
[56] T.W. Loo, D.M. Clarke, Cross-linking of human multidrug resistance P-glycoprotein by
the substrate, tris-(2-maleimidoethyl) amine, is altered by ATP hydrolysis evidence
for rotation of a transmembrane helix, J. Biol. Chem. 276 (2001) 31800–31805.
[57] T.W. Loo, D.M. Clarke, Drug rescue distinguishes between different structural
models of human P-glycoprotein, Biochemistry 52 (2013) 7167–7169.
[58] T.W. Loo, D.M. Clarke, A salt bridge in intracellular loop 2 is essential for folding of
human P-glycoprotein, Biochemistry 52 (2013) 3194–3196.
[59] X. Zhang, K.I. Collins, L.M. Greenberger, Functional evidence that transmembrane 12
and the loop between transmembrane 11 and 12 form part of the drug-binding
domain in P-glycoprotein encoded by MDR1, J. Biol. Chem. 270 (1995) 5441–5448.
[60] I.L. Urbatsch, B. Sankaran, S. Bhagat, A.E. Senior, Both P-glycoprotein nucleotide-
binding sites are catalytically active, J. Biol. Chem. 270 (1995) 26956–26961.
[61] M.L. Oldham, J. Chen, Snapshots of the maltose transporter during ATP hydrolysis,
Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 15152–15156.
[62] J.G. Wise, Catalytic transitions in the human MDR1 P-glycoprotein drug-binding
sites, Biochemistry 51 (2012) 5125–5141.[63] T.W. Loo, D.M. Clarke, Location of the rhodamine-binding site in the human multi-
drug resistance P-glycoprotein, J. Biol. Chem. 277 (2002) 44332–44338.
[64] S. Dey, M. Ramachandra, I. Pastan, M.M. Gottesman, S.V. Ambudkar, Evidence for
two nonidentical drug-interaction sites in the human P-glycoprotein, Proc. Natl.
Acad. Sci. U. S. A. 94 (1997) 10594–10599.
[65] C. Pascaud, M. Garrigos, S. Orlowski, Multidrug resistance transporter P-glycoprotein
has distinct but interacting binding sites for cytotoxic drugs and reversing agents,
Biochem. J. 333 (1998) 351–358.
[66] A.B. Shapiro, K. Fox, P. Lam, V. Ling, Stimulation of P-glycoprotein-mediated drug
transport by prazosin and progesterone, Eur. J. Biochem. 259 (1999) 841–850.
[67] M.R. Lugo, F.J. Sharom, Interaction of LDS-751 with P-glycoprotein and mapping of
the location of the R drug-binding site, Biochemistry 44 (2005) 643–655.
[68] T.W. Loo, M.C. Bartlett, D.M. Clarke, Permanent activation of the human P-
glycoprotein by covalent modiﬁcation of a residue in the drug-binding site, J. Biol.
Chem. 278 (2003) 20449–20452.
[69] T.W. Loo, D.M. Clarke, Identiﬁcation of the distance between the homologous halves
of P-glycoprotein that triggers the high/low ATPase activity switch, J. Biol. Chem.
289 (2014) 8484–8492.
[70] T.W. Loo, D.M. Clarke, Functional consequences of phenylalanine mutations in the
predicted transmembrane domain of P-glycoprotein, J. Biol. Chem. 268 (1993)
19965–19972.
[71] I.K. Pajeva, C. Globisch, M. Wiese, Structure–function relationships of multidrug
resistance P-glycoprotein, J. Med. Chem. 47 (2004) 2523–2533.
[72] T.W. Loo, M.C. Bartlett, D.M. Clarke, Substrate-induced conformational changes in
the transmembrane segments of human P-glycoprotein. Direct evidence for the
substrate-induced ﬁt mechanism for drug binding, J. Biol. Chem. 278 (2003)
13603–13606.
[73] T.W. Loo, D.M. Clarke, Locking intracellular helices 2 and 3 together inactivates
human P-glycoprotein, J. Biol. Chem. 289 (2014) 229–236.
[74] T.W. Loo, M.C. Bartlett, D.M. Clarke, Simultaneous binding of two different drugs in
the binding pocket of the human multidrug resistance P-glycoprotein, J. Biol. Chem.
278 (2003) 39706–39710.
[75] T.W. Loo, M.C. Bartlett, D.M. Clarke, Drug binding in human P-glycoprotein causes
conformational changes in both nucleotide-binding domains, J. Biol. Chem. 278
(2003) 1575–1578.
[76] T.W. Loo, M.C. Bartlett, D.M. Clarke, Nucleotide binding, ATP hydrolysis, and mutation
of the catalytic carboxylates of human P-glycoprotein cause distinct conformational
changes in the transmembrane segments, Biochemistry 46 (2007) 9328–9336.
